Verificando…
Traducido automáticamente. Dosis y advertencias: consulta el original en inglés. Leer en inglés
Inicio / Registrado en Nigeria / Fluimucil 600 mg Effervescent Tablets

Fluimucil 600 mg Effervescent Tablets

NAFDAC Reg. No. B4-2557 Estupefaciente

Registrado en NAFDAC. Registro activoAs of 6 November 2026 · synced automatically from official sources.
Producto
Fluimucil 600 mg Effervescent Tablets
Número NAFDAC
B4-2557
Principio activo
Acetylcysteine
Dosis
600 mg
Forma
Effervescent tablet
Tamaño del envase
1 x 10's (in blister)
Fabricante
No Constan
Solicitante (titular)
Phillips Pharmaceuticals (Nigeria) Limited
Approved
30 Nov 2023
Estado
Activo Ver en NAFDAC ↗
Registro válido hasta
29 Nov 2028
Alertas de la OMS
No se ha encontrado ninguno
Informes de la comunidad
Ninguno
Tiempos comprobados
0

Pero sobre el medicamento, Acetylcysteine: uses, dosage and brands worldwide

Lo que encontramos

  • Fluimucil 600 mg Effervescent Tablets is on the NAFDAC register with an active registration (B4-2557). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generado automáticamente a partir del registro NAFDAC, QUIÉN alerta y los datos de la comunidad a partir de hoy. Este no es un consejo médico. Siga siempre a su médico o farmacéutico.

How to use Fluimucil 600 mg Effervescent Tablets

Lo que dice el prospecto oficial. Si te lo recetó un médico, sigue la receta. Si el prospecto de tu caja es distinto, manda el de tu caja.

Para quién es

Acetylcysteine Injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). Acetylcysteine Injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with an acute ingestion or from repeated supratherapeutic ingestion (RSI) ( 1 ).

Cómo tomarlo y con qué frecuencia
  • Pre-Treatment Assessment Following Acute Ingestion : Obtain a plasma or serum sample to assay for acetaminophen concentration at least 4 hours after ingestion
  • If the time of acetaminophen ingestion is unknown: Administer a loading dose of acetylcysteine injection immediately
  • Obtain an acetaminophen concentration to determine need for continued treatment
  • If the acetaminophen concentration cannot be obtained (or is unavailable or uninterpretable) within the 8-hour time interval after acetaminophen ingestion or there is clinical evidence of acetaminophen toxicity: Administer a loading dose of acetylcysteine injection immediately and continue treatment for a total of three doses over 21 hours
  • If the patient presents more than 8 hours after ingestion and the time of acute acetaminophen ingestion is known: Administer a loading dose of acetylcysteine injection immediately
  • Obtain acetaminophen concentration to determine need for continued treatment
  • If the patient presents less than 8 hours after ingestion and the time of acute acetaminophen ingestion is known and the acetaminophen concentration is known: Use the Rumack-Matthew nomogram ( Figure 1 ) to determine whether or not to initiate treatment with acetylcysteine injection
  • Nomogram for Estimating Potential for Hepatotoxicity from Acute Acetaminophen Ingestion : See Full Prescribing Information for instructions on how to use the nomogram to determine the need for dosing. …
Fortalezas en las que viene

Acetylcysteine Injection: 200 mg per mL (6 grams of acetylcysteine in 30 mL) in a single-dose vial. Acetylcysteine Injection: 6 grams per 30 mL (200 mg per mL) in a single-dose vial ( 3 ).

Infancia
  • Safety and effectiveness of acetylcysteine
  • In pediatric patients have not been established by adequate and well-controlled studies
  • Use of acetylcysteine
  • In pediatric patients 5 kg and greater is based on clinical practice [see Dosage and Administration ]
While you are taking it
  • Hypersensitivity Reactions Advise patients and caregivers that hypersensitivity reactions related to administration and infusion may occur during and after acetylcysteine treatment, including hypotension, wheezing, shortness of breath and bronchospasm [see Warnings and Precautions ]
  • For specific treatment information regarding the clinical management of acetaminophen overdose, please contact your regional poison center at 1-800-222-1222, or alternatively, a special health professional assistance line for acetaminophen overdose at 1-800-525-6115
  • Mfd. for SAGENT Pharmaceuticals Schaumburg, IL 60195 (USA) Made in Italy Novaplus is a registered trademark of Vizient, Inc. …
Talk to a doctor first if
  • Acetylcysteine is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see Warnings and Precautions ]
  • Patients with a previous hypersensitivity reaction to acetylcysteine
Warnings

Hypersensitivity Reactions, Including Hypotension, Wheezing, Shortness of Breath and Bronchospasm: Observe patients during and after the infusion; immediately discontinue infusion if a serious reaction occurs and initiate appropriate treatment. Acetylcysteine infusion may be carefully restarted after treatment of hypersensitivity has been initiated ( 5.1 ). Fluid Overload: Total volume administered should be reduced for patients weighing less than 40 kg and for those requiring fluid restriction ( 5.2 ). …

Posibles efectos secundarios

Most common adverse reactions (> 2%) are rash, urticaria/facial flushing and pruritus ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals, Inc. at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In the literature the most frequently reported adverse reactions attributed to intravenous acetylcysteine administration were rash, urticaria and pruritus. …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary Limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. Delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see Clinical Considerations ]. …

If you take too much

An initial 150 mg/kg dose of acetylcysteine for a patient weighing 106 kg was mistakenly calculated as 160 g (a decimal point error resulting in a 10-fold higher than prescribed dose). An hour after the infusion started, the patient complained of generalized heat sensation and body pain and developed widespread urticaria and hypotension. The second acetylcysteine infusion was withheld and the patient was treated for anaphylaxis. Despite treatment the patient succumbed to the acute inflammatory reaction and died. …

How to store it

Storage Conditions Store unopened vials at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Discard unused portion. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex.

Si olvidas una dosis

Tómala en cuanto te acuerdes, salvo que falte poco para la siguiente. En ese caso, sáltate la olvidada. Nunca tomes dos dosis a la vez para compensar. Revisa tu prospecto, porque algunos medicamentos son distintos.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2022-04-05.

Label for acetylcysteine, the active ingredient registered with NAFDAC.

Check your pack of Fluimucil 600 mg Effervescent Tablets

Add the expiry date on your pack for a full Trust Score.

O haz fotos de la caja
Te quedan 3 verificaciones gratis hoy Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Fluimucil 600 mg Effervescent Tablets

What is in Fluimucil 600 mg Effervescent Tablets?

Fluimucil 600 mg Effervescent Tablets contains Acetylcysteine (600 mg), as effervescent tablet, according to its NAFDAC registration record.

Is Fluimucil 600 mg Effervescent Tablets registered with NAFDAC?

Yes. Fluimucil 600 mg Effervescent Tablets is listed on the NAFDAC register under registration number B4-2557, and its registration is active as of 6 November 2026.

Has Fluimucil 600 mg Effervescent Tablets been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Fluimucil 600 mg Effervescent Tablets in our automatically synced alert list.

How can I check that my pack of Fluimucil 600 mg Effervescent Tablets is genuine?

Run a free authenticity scan with the NAFDAC number B4-2557, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Fluimucil 600 mg Effervescent Tablets?

Follow your prescription or the leaflet in your pack. The official label says: Pre-Treatment Assessment Following Acute Ingestion ( 2.1 ) : Obtain a plasma or serum sample to assay for acetaminophen concentration at least 4 hours after ingestion. If the time of acetaminophen ingestion is unknown: Administer a loading dose of acetylcysteine injection immediately. Obtain an acetaminophen concentration to determine need for continued treatment. If the acetam…

What is Fluimucil 600 mg Effervescent Tablets used for?

Acetylcysteine Injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). Acetylcysteine Injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of a (Summarised from the official U.S. FDA label for acetylcysteine. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Fluimucil 600 mg Effervescent Tablets? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.